Today's top medical abstracts
Rheumatology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Rheumatology
For Practicing
Rheumatologists
Conferences
Jobs
Newsletters
My Library
Topics in
Rheumatology
        Amyloidosis
        Autoimmune/Heritable
        Basic Science/Genetics
        Bone Metabolism
        Chr Fatigue/Fibromyalgia
        Clinical Pharmacology
        Connective Tissue Dz
        Diagnostics/Radiology
        Economics of Medicine
        Gout and Hyperuricemia
        Infectious Arthritis
        Osteoarthritis
        Other Arthritis
        Pediatric Rheumatology
        Popular Press
        Rheumatoid Arthritis
        Spondylarthropathies
        Systemic Lupus (SLE)
        Vasculitic Syndromes
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
For Practicing Rheumatologists
Today's Rheumatology News: VGX-1027 To Undergo Additional Testing For RA
D Scott Cunningham MD, PhD, MDLinx Rheumatology
Today's Rheumatology News: FDA Approves Actemra
D Scott Cunningham MD, PhD, MDLinx Rheumatology
From the Editors: New Clinical-Only Option for MDLinx!
Stephen Smith, MDLinx
  See all
human osteoarthritic subchondral bone osteoblasts Article Summary

Print     Email This Article     Save in My Library   Free Abstract
Tat SK et al. – Osteoprotegerin (OPG) and receptor activator of nuclear factor κB ligand (RANKL) levels, and consequently the OPG/RANKL ratio, differed according to human OA subchondral bone osteoblast classification; it is decreased in L and increased in H OA. These findings strongly suggest that the metabolic state of the L OA osteoblasts favours bone resorption.

Methods
  • Study to investigate the OPG and RANKL expression levels, the histologic analysis of the subchondral bone as well as the osteoclast differentiation effect of osteoblasts
  • Gene expression was determined using RT-PCR, PGE2 and OPG levels by specific ELISA, and membranous RANKL by flow cytometry
  • Histological observation of the subchondral bone was performed on human knee specimens
  • Osteoclast differentiation and formation was assayed by using the pre-osteoclastic cell line RAW 264.7
  • OPG and RANKL modulation on L OA osteoblasts was monitored following treatment with osteotropic factors
  • Resorption activity was studied by the co-culture of differentiated PBMC/osteoblasts

Results
  • Human OA subchondral bone osteoblasts expressed less OPG than normal
  • Compared to normal, RANKL gene expression levels were increased in L OA and decreased in H OA cells
  • The OPG/RANKL mRNA ratio was diminished in L OA vs normal or H OA and markedly increased in H OA vs normal
  • Inhibition of endogenous PGE2 levels by indomethacin markedly decreased the ratio of OPG/RANKL on the H OA
  • In contrast to H OA osteoblasts, L OA cells induced a higher level of osteoclast differentiation and formation
  • A reduced subchondral bone on the L OA and an increased bone mass on the H OA was observed vs normal
  • OPG/RANKL mRNA expression ratio was reduced by vit D3 and increased by TNF-α, PTH and PGE2, while IL-1β demonstrated no effect
  • OPG protein levels showed similar profiles
  • No true effect was noted on membranous RANKL upon treatment with IL-1β, PGE2 and PTH, but an increase was observed with vit D3 and TNF-α
  • The resorption activity of the L OA cells was inhibited by all treatments except IL-1β, with maximum effect observed with vit D3 and PGE2

Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.